The 28 references in paper A. Vizel' A., I. Vizel' Yu., А. Визель А., И. Визель Ю. (2016) “ДуоРесп Спиромакс® – новый интуитивный дозирующий порошковый ингалятор будесонида и формотерола // DuoResp Spiromax® is a new intuitive dosing dry powder inhaler of budesonide and formoterol” / spz:neicon:pulmonology:y:2016:i:4:p:498-504

1
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation.Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 963–974.
(check this in PDF content)
2
Adeloye D., Chua S., Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and metaanalysis.J. Glob. Health. 2015; 5 (2): 020415.
(check this in PDF content)
3
Braido F., Brusselle G., Guastalla D. et al. Determinants and impact of suboptimal asthma control in Europe: The international cross-sectional and longitudinal assessment on asthma control (LIAISON) study.Respir. Res. 2016; 17 (1): 51.
(check this in PDF content)
4
Global initiative for asthma (GINA). A pocket guide for health professionals: Updated 2016.
(check this in PDF content)
5
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): Updated 2016.
(check this in PDF content)
6
Baker J.G. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br. J. Pharmacol.2010; 160 (5): 1048–1061.
(check this in PDF content)
7
Willey R.F., Godden D.J., Carmichael J. et al. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma.Br. J. Dis. Chest.1982; 76 (1): 61–68.
(check this in PDF content)
8
LähelmäS., Sairanen U., Haikarainen J. et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 462–473.
(check this in PDF content)
9
Latorre M., Novelli F., Vagaggini B. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS) / long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm. Pharmacol. Ther. 2015; 30: 44–50.
(check this in PDF content)
10
Hozawa S., Terada M., Haruta Y., Hozawa M. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy. Pulm. Pharmacol. Ther. 2016; 37: 15–23.
(check this in PDF content)
11
Kew K.M., Karner C., Mindus S.M., Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013; 12: CD009019.
(check this in PDF content)
12
Ekberg-Jansson A., Svenningsson I., Rågdell P. et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE). 12. Int. J. Clin. Pract. 2015; 69 (10): 1171–1178.
(check this in PDF content)
13
Scichilone N., Benfante A., Bocchino M. et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm. Pharmacol. Ther.2015; 31: 63–67.
(check this in PDF content)
14
Cohen J.S., Miles M.C., Donohue J.F., Ohar J.A. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.Int. J. Chron. Obstruct. Pulm. Dis.2016; 11: 785–797.
(check this in PDF content)
15
Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies: ERS/ISAM task force report. Eur. Respir. J. 2011; 37 (6): 1308–1331.
(check this in PDF content)
16
Wilson D.S., Gillion M.S., Rees P.J. Use of dry powder inhalers in COPD. Int. J. Clin. Pract.2007; 61 (12): 2005–2008.
(check this in PDF content)
17
Wieshammer S., Dreyhaupt J. Dry powder inhalers: Which factors determine the frequency of handling errors? Respiration. 2008; 75:1 8–25.
(check this in PDF content)
18
Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control.Respir. Med. 2011; 105 (6): 930–938.
(check this in PDF content)
19
Basheti I.A., Obeidat N.M., Ammari W.G., Reddel H.K. Associations between inhaler technique and asthma control among asthma patients using pressurised MDIs and DPIs. Int. J. Tuberc. Lung Dis.2016; 20 (5): 689–695.
(check this in PDF content)
20
Kondo T., Tanigaki T., Hibino M. et al. Resistances of dry powder inhalers and training whistles and their clinical significance. Arerugi. 2014; 63 (10): 1325–1329.
(check this in PDF content)
21
Wolthers O.D., Shah T.A Comparison of short-term growth during treatment with two dry powder combinations of inhaled corticosteroids and long-acting β2-agonists. J. Aerosol. Med. Pulm. Drug Deliv.2015; 28 (3): 182–188.
(check this in PDF content)
22
Canonica G.W., Arp J., Keegstra J.R., Chrystyn H. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (5): 309–319.
(check this in PDF content)
23
Virchow J.C., Rodriguez-Roisin R., Papi A. et al. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax®compared to budesonide-formoterol Turbuhaler®in adults and adolescents with persistent asthma. BMC Pulm. Med. 2016; 16: 42.
(check this in PDF content)
24
Azouz W., Chetcuti P., Hosker H. et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax®and Turbuhaler®devices: a randomised, cross-over study. BMC Pulm. Med.2015; 15: 47.
(check this in PDF content)
25
Plusa T. Pijos P. Features of the ideal inhaler in testing a new inhaler devices. Int. Rev. Allergol. Clin. Immunol. Familiy Med.2015; 21 (1): 21–24.
(check this in PDF content)
26
Sandler N., Holländer J., Långström D. et al. Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler). Br. Med. J. Open Respir. Res. 2016; 3 (1): e000119.
(check this in PDF content)
27
Chrystyn H., Safioti G., Keegstra J.R., Gopalan G. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. Int. J. Pharm.2015; 491 (1–2): 268–276.
(check this in PDF content)
28
Torvinen S., Nicolai J., Pulimeno S. et al. The budget impact of Duoresp®Spiromax®compared with commonly prescribed dry powder inhalers for the management of asthma and chronic obstructive pulmonary disease in Italy: estimated impact of inhalation technique. Value Health. 2015;
(check this in PDF content)